空间组学市场 - 按技术、产品、应用、工作流程、样本类型、最终用途、2024 - 2032 年全球预测

由于合作和伙伴关係数量不断增加，2024 年至 2032 年全球空间组学市场规模预计将呈现 14.3% 的复合年增长率。最近，研究人员和公司正在积极联手开发先进的影像技术和计算工具。这些措施的重点是揭示细胞相互作用和组织结构的新见解。此外，这种合作伙伴关係将继续发展，以整合人工智慧和机器学习，以更有效地分析复杂的资料集。

增强空间解析度能力和扩大疾病研究、个人化医疗和药物发现应用的不断进步，塑造生物医学的未来，将推动产业成长。例如，2024 年 3 月，Firalis Molecular Precision (FMP) 与 Vizgen 合作，为欧洲研究人员启动了一项资助计画。这项措施有助于推进空间组学技术，透过创新研究计画增强对细胞层级生物系统的理解。

空间组学市场分为技术、产品、应用、工作流程、样本类型、最终用途和区域。

从产品来看，仪器领域预计从 2024 年到 2032 年将大幅成长，因为它们能够提供有关细胞和组织结构的高解析度和空间分辨资料。研究人员正在使用先进的成像系统和分子分析工具来绘製基因和蛋白质在其空间背景下的表达图。此外，持续改进正在增强仪器灵敏度、速度和资料整合能力。最近的进展也为药物发现、疾病研究和个人化医疗中复杂生物系统的更精确分析铺平了道路。

製药和生物技术最终用途领域的太空组学产业预计将从 2024 年扩大到 2032 年。他们正在利用空间分辨资料来更全面地了解复杂的生物机制和疾病途径。此外，这些公司越来越多地与学术机构和技术提供者合作，以完善分析技术和计算工具。

从地区来看，在医疗保健支出不断增长以及对药物发现和开发的持续关注的推动下，欧洲空间组学行业规模预计将在 2024 年至 2032 年间出现强劲增长。该地区的政府和私营部门正在投资先进技术，以加强生物医学研究并改善医疗保健成果。此外，整合空间组学以增强资料分析能力以及促进研究机构和製药公司之间的合作以推动疾病理解和治疗方面的突破将有利于区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 组学技术的进步
    • 个人化医疗中的应用不断增加
    • 政府措施和资金不断增加
  • 产业陷阱与挑战
    • 仪器和资料储存成本高
    • 复杂的监管要求和标准化问题
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按技术分类，2021 - 2032 年

• 主要趋势
• 空间转录组学
• 空间基因体学
• 空间蛋白质体学

第 6 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 仪器
  • 按模式
    • 自动化
    • 半自动化
    • 手动的
  • 按类型
    • 定序平台
    • 免疫组化
    • 显微镜检查
    • 流式细胞仪
    • 质谱
    • 其他类型
• 耗材
• 软体
  • 生物资讯学工具
  • 影像工具
  • 储存和管理资料库

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 诊断
• 翻译研究
• 药物发现与开发
• 单细胞分析
• 细胞生物学
• 其他应用

第 8 章：市场估计与预测：按工作流程，2021 - 2032

• 主要趋势
• 样品製备
• 仪器分析
• 数据分析

第 9 章：市场估计与预测：按样本类型，2021 - 2032

• 主要趋势
• 福马林固定石蜡包埋 (FFPE)
• 新鲜冷冻

第 10 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 学术及研究机构
• 製药和生物技术公司
• 合约研究组织
• 其他最终用户

第 11 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 12 章：公司简介

• 10x Genomics
• Akoya Biosciences, Inc.
• Bio-Techne Corporation
• BioSpyder, Inc.
• Bruker Corporation
• Danaher Corporation
• Diagenode Diagnostics (Hologic, Inc.)
• Ionpath, Inc.
• Millennium Science Pty Ltd.
• NanoString Technologies, Inc.
• PerkinElmer, Inc.
• S2 Genomics, Inc.

Global Spatial OMICS Market size is expected to exhibit 14.3% CAGR from 2024 to 2032, due to the increasing number of collaborations and partnerships. Of late, researchers and companies are actively joining forces to develop advanced imaging techniques and computational tools. These initiatives are focused on uncovering new insights into cellular interactions and tissue architecture. Moreover, such partnerships will continue to evolve for integrating AI and machine learning to analyze complex datasets more efficiently.

The increasing advancements for enhancing spatial resolution capabilities and expanding applications in disease research, personalized medicine, and drug discovery for shaping the future of biomedical sciences will drive the industry growth. For instance, in March 2024, Firalis Molecular Precision (FMP) partnered with Vizgen to launch a Grant Program for European researchers. This initiative helped to advance spatial omics technology for enhancing the understanding of biological systems at the cellular level through innovative research projects.

The spatial OMICS market is segregated into technology, product, application, workflow, sample type, end-use, and region.

By product, the instruments segment is estimated to rise at significant rate from 2024 to 2032, due to their ability to provide high-resolution and spatially resolved data on cellular and tissue architecture. Researchers are using advanced imaging systems and molecular profiling tools to map gene and protein expressions within their spatial context. In addition, continuous improvements are enhancing instrument sensitivity, speed, and data integration capabilities. Recent advancements are also making way for more precise analysis of complex biological systems in drug discovery, disease research, and personalized medicine.

Spatial OMICS industry from the pharmaceutical and biotechnology end-use segment is expected to expand from 2024 to 2032. Of late, pharmaceutical and biotechnology companies are integrating spatial omics technology to advance drug discovery and development processes. They are leveraging spatially resolved data to understand complex biological mechanisms and disease pathways more comprehensively. Moreover, these firms are increasingly collaborating with academic institutions and technology providers to refine analytical techniques and computational tools.

Regionally, the Europe spatial OMICS industry size is projected to depict robust growth between 2024 and 2032, propelled by the rising healthcare expenditure and the ongoing focus on drug discovery and development. Governments and private sectors in the region are investing in advanced technologies to enhance biomedical research and improve healthcare outcomes. Additionally, increasing developments for integrating spatial OMICS for enhancing data analysis capabilities as well as fostering collaborations between research institutions and pharmaceutical companies to drive breakthroughs in disease understanding and treatment will favor the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancements in omics technologies
    • 3.2.1.2 Increasing applications in personalized medicine
    • 3.2.1.3 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of instruments and data storage
    • 3.2.2.2 Complex regulatory requirements and standardization issues
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Spatial transcriptomics
• 5.3 Spatial genomics
• 5.4 Spatial proteomics

Chapter 6 Market Estimates and Forecast, By Products, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Instruments
  • 6.2.1 By Mode
    • 6.2.1.1 Automated
    • 6.2.1.2 Semi-automated
    • 6.2.1.3 Manual
  • 6.2.2 By Type
    • 6.2.2.1 Sequencing platforms
    • 6.2.2.2 IHC
    • 6.2.2.3 Microscopy
    • 6.2.2.4 Flow cytometry
    • 6.2.2.5 Mass spectrometry
    • 6.2.2.6 Other types
• 6.3 Consumables
• 6.4 Software
  • 6.4.1 Bioinformatics tools
  • 6.4.2 Imaging tools
  • 6.4.3 Storage & management databases

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Diagnostics
• 7.3 Translation research
• 7.4 Drug discovery and development
• 7.5 Single cell analysis
• 7.6 Cell biology
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Workflow, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Sample preparation
• 8.3 Instrumental analysis
• 8.4 Data analysis

Chapter 9 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Formalin-Fixed Paraffin-Embedded (FFPE)
• 9.3 Fresh frozen

Chapter 10 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Academic & research institutes
• 10.3 Pharmaceutical and biotechnology companies
• 10.4 Contract research organizations
• 10.5 Other end-users

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
  • 11.3.7 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE
  • 11.6.4 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 10x Genomics
• 12.2 Akoya Biosciences, Inc.
• 12.3 Bio-Techne Corporation
• 12.4 BioSpyder, Inc.
• 12.5 Bruker Corporation
• 12.6 Danaher Corporation
• 12.7 Diagenode Diagnostics (Hologic, Inc.)
• 12.8 Ionpath, Inc.
• 12.9 Millennium Science Pty Ltd.
• 12.10 NanoString Technologies, Inc.
• 12.11 PerkinElmer, Inc.
• 12.12 S2 Genomics, Inc.